EN
登录

私人对冲基金赞助机构Perceptive Advisors完成收购Synthego

Synthego Announces Successful Close of Acquisition by Perceptive Advisors

CISION 等信源发布 2025-07-21 19:00

可切换为仅中文


REDWOOD CITY, Calif.

加利福尼亚州红木城

,

July 21, 2025

2025年7月21日

/PRNewswire/ -- Synthego, a leading provider of CRISPR solutions, today announced the successful closing of the acquisition of substantially all of its assets by funds managed by Perceptive Advisors, a leading life sciences investment firm. The transaction officially closed on

/PRNewswire/ -- Synthego,一家领先的CRISPR解决方案提供商,今天宣布由Perceptive Advisors管理的基金成功完成了对其绝大部分资产的收购。该交易已正式完成于

July 18, 2025

2025年7月18日

.

Under the new ownership of the Perceptive funds, Synthego will continue its operations as normal, maintaining its commitment to delivering high-quality CRISPR products and services to its global clientele. The company's leadership team and dedicated staff remain in place, ensuring seamless continuity in day-to-day operations and customer support.

在Perceptive基金的新所有权下,Synthego将继续正常运营,坚持为全球客户提供高质量的CRISPR产品和服务。公司的领导团队和专业员工保持不变,确保日常运营和客户支持的无缝衔接。

The Synthego brand identity will continue, and the web and email domain remain .

Synthego 品牌标识将继续存在,网站和电子邮件域名保持不变。

synthego.com

synthego.com

.

'We are thrilled to officially complete this transaction and embark on a new chapter with Perceptive Advisors,' said

“我们很高兴正式完成这项交易,并与Perceptive Advisors一起开启新的篇章,”

Craig Christianson

克雷格·克里斯蒂安森

, CEO of Synthego. 'This partnership strengthens our financial position and provides us with enhanced resources to accelerate innovation and expand our product portfolio in the months ahead. We remain fully committed to supporting our clients in their groundbreaking research and therapeutic development efforts.'.

Synthego首席执行官表示:“此次合作加强了我们的财务状况,并为我们提供了更多资源,以加速创新并在未来几个月内扩展我们的产品组合。我们仍然全力致力于支持客户在开创性研究和治疗开发方面的工作。”

The Perceptive funds' acquisition reinforces Synthego's mission to empower scientific discovery through advanced genomic engineering. Synthego will continue to manufacture its best-in-class guide RNA in

Perceptive基金的收购进一步巩固了Synthego通过先进基因组工程推动科学发现的使命。Synthego将继续生产其一流的引导RNA,

Redwood City, California

加利福尼亚州红木城

, ensuring this essential component is made in the

,确保这一重要组件被制造在

USA

美国

and supports the development of CRISPR-based therapies for the global market. Synthego launched a GMP offering of SpCas9 in May and recently expanded gene editing options with launches of eSpOT-ON and Accubase™ enzymes in July, along with related guide RNA offerings.

并支持基于CRISPR疗法的全球市场开发。Synthego于五月推出了符合GMP标准的SpCas9产品,并于七月通过推出eSpOT-ON和Accubase™酶以及相关的引导RNA产品,进一步扩展了基因编辑选项。

'We're incredibly excited about working closely with Perceptive Advisors. Our customers' successes inspire us daily, and this partnership ensures we can both expand our offerings and accelerate our mission to deliver the most advanced and reliable CRISPR solutions for their critical work,' said

“我们非常高兴能与Perceptive Advisors紧密合作。客户的成功每天都在激励着我们,此次合作确保我们既能扩展我们的产品,又能加速推进我们的使命,为他们的关键工作提供最先进、最可靠的CRISPR解决方案,”

Jason Miller

杰森·米勒

, Chief Commercial Officer of Synthego.

Synthego首席商务官。

About Perceptive Advisors

关于Perceptive Advisors

Founded in 1999 and based in

成立于1999年,总部位于

New York, NY

纽约,纽约州

, Perceptive Advisors is an investment management firm with approximately

,Perceptive Advisors是一家投资管理公司,拥有大约

$7 billion

70亿美元

in assets. Perceptive Advisors is focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare. For more information visit

在资产方面。Perceptive Advisors 专注于通过识别机会并将其财务资源导向医疗保健领域最有前途的技术,来支持生命科学行业的进步。欲了解更多信息,请访问

www.perceptivelife.com

www.perceptivelife.com

.

About Synthego

关于Synthego

Synthego is a leading provider of CRISPR solutions, enabling the acceleration of life science research and therapeutic development. The company's innovative portfolio of CRISPR-engineered products and services empowers scientists to achieve unparalleled precision and reproducibility in their experiments, from basic research to clinical applications..

Synthego是CRISPR解决方案的领先提供商,致力于加速生命科学研究和治疗开发。公司创新的CRISPR工程产品和服务组合帮助科学家在从基础研究到临床应用的实验中实现无与伦比的精确性和可重复性。

SOURCE Synthego

来源:Synthego

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗?

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM?

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9千+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用